CG Oncology, Inc.·4

Mar 6, 5:52 PM ET

Kuan Arthur 4

Research Summary

AI-generated summary

Updated

CG Oncology CEO Arthur Kuan Exercises Options (Net Exercise)

What Happened
Arthur Kuan, CEO of CG Oncology (CGON), exercised options on March 4, 2026. He exercised options to purchase 102,871 shares at $1.72 per share (aggregate exercise amount ≈ $176,938) and, per the filing, received 100,000 shares net. The company withheld 2,871 shares to satisfy tax withholding (valued at $61.61/share, ≈ $176,882). The filing notes the reporting person also paid cash to cover the delta of the aggregate exercise price. The company classed the action as an option exercise (code M) with a tax‑withholding disposition (code F); the transaction is not a sale.

Key Details

  • Transaction date: 2026-03-04; Form filed: 2026-03-06 (timely).
  • Options exercised: 102,871 shares at $1.72/share (total ≈ $176,938).
  • Net shares received: 100,000; 2,871 shares withheld for taxes (valued ≈ $176,882).
  • Footnotes: F1 confirms a net (cashless) exercise and that the withholding does not represent a sale; F2 states the option was vested and exercisable.
  • Shares owned after transaction: not disclosed in this filing.

Context
This was a net/cashless option exercise: options were converted into stock, with a small portion of shares withheld to cover tax obligations and the filer paying cash to satisfy the exercise price/delta. Net exercises are routine corporate actions and do not on their own indicate intent to buy or sell stock in the open market.